Alligator Bioscience AB (publ) Interim report January-June 2020

R

Promising safety data for ATOR-1015
“With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinical development portfolio. ATOR-1015 has received a great deal of attention in connection with the positive interim data presented at AACR and ASCO, the world’s two largest oncology conferences. We have also worked actively with business development and signed a research agreement with Scandion Oncology during the period, while our collaboration with Biotheus developed well and led to an additional milestone payment. The Covid-19 pandemic has been stressful but has not led to any serious delays in the clinical projects. We are now looking forward to an exciting second half of 2020 for Alligator”, commented CEO Per Norlén.

Alligator Bioscience AB (publ) Interim report January-March 2020

R

Stronger focus on clinical projects “The focusing of our operations protects the company’s liquidity, but is also part of our long-term strategy with a emphasis on clinical projects and innovation,” CEO Per Norlén comments. Significant events January-March • Andreas Johannesson was appointed interim CFO. • The COVID-19 pandemic impacts the recruitment of new patients to […]

Alligator Bioscience’s Annual Report 2019 published

R

Lund, Sweden, 2 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the Swedish version of the Annual Report 2019 is available on the company website http://www.alligatorbioscience.com. An English version will follow shortly. For further information, please contact: Cecilia Hofvander, Director Investor Relations & […]

Alligator Bioscience AB Interim report January-September 2019

R

“We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to, with or without a new partner, bring ADC-1013 into Phase II clinical trials next year. In total, we now have three projects in clinical development, and soon another one where the first […]

Alligator Bioscience’s Annual Report 2018 published

R

Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the Annual Report 2018 is available at the company website http://www.alligatorbioscience.com. For further information, please contact:Cecilia Hofvander, Director Investor Relations & CommunicationsPhone +46 46 540 82 06E-mail: cecilia.hofvander@alligatorbioscience.com. This information is such information […]